Rising early-onset neuroendocrine tumors reveal unique challenges and disparities, highlighting the need for tailored care and research focused on younger patients.
Videos
John L. Marshall, MD, discusses the challenges faced by oncologists in managing colorectal cancer treatments seen during a Case-Based Roundtable event.
Dr Vishal A. Patel explores critical scenarios for using cemiplimab in treating high-risk cutaneous squamous cell carcinoma, enhancing patient outcomes through tailored strategies.
An expert discusses the evolving treatment landscape for EGFR-mutated non–small cell lung cancer (NSCLC), highlighting the frontline shift of targeted therapies like those in MARIPOSA, the growing complexity of treatment sequencing, and the importance of patient education and clinical trial participation in navigating this transformative era of care.
Dr Vishal A. Patel discusses innovative strategies for optimizing cemiplimab in treating high-risk cutaneous squamous cell carcinoma and enhancing patient outcomes.
Dr Patel highlights the groundbreaking C-POST trial results, showcasing cemiplimab's significant impact on disease-free survival in high-risk CSCC patients.
Dr Vishal A. Patel discusses the breakthrough in treating high-risk cutaneous squamous cell carcinoma with FDA-approved cemiplimab, addressing significant patient needs.
A panelist discusses how early relapse and prognostic indicators shape second-line therapy selection and emerging treatment roles.
A panelist discusses how patient comorbidities and declining performance status drive individualized treatment planning in relapsed ES-SCLC.
Dr Vishal A. Patel discusses the design and patient criteria for the pivotal C-POST trial evaluating adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma.
Bradley Monk, MD, highlights transformative long-term outcomes from the innovaTV trial, showcasing innovative treatments for cervical cancer at ESMO 2025.
Scott Tagawa, MD, highlights the PSMAddition trial's promising results, showcasing Lutetium-177 PSMA-617's significant benefits for advanced prostate cancer treatment.
Justin Watts, MD, discusses key findings from a study of olutasidenib in patients with IDH1-mutated myelodysplastic syndrome.
Dr Bradley J. Monk explores the RUBY trial's findings, highlighting the survival benefits of adding dostarlimab to chemotherapy for endometrial cancer treatment.
Recent studies reveal that triplet therapies significantly enhance progression-free survival in patients with endocrine-resistant breast cancer.
Atezolizumab significantly enhances survival in ctDNA-positive muscle-invasive bladder cancer patients, addressing critical treatment gaps post-surgery.
An expert discusses the successful long-term use of amivantamab in frontline regimens like MARIPOSA, emphasizing the importance of proactive adverse effect management, patient education, and team-based care in supporting adherence and delivering sustainable, patient-centered cancer treatment.
Dr. Joyce O'Shaughnessy discusses the monarchE trial's findings, emphasizing the importance of abemaciclib in reducing breast cancer recurrence and improving patient access.
New findings from the monarchE trial reveal long-term benefits of abemaciclib in reducing recurrence risk for high-risk early breast cancer patients.
Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of avelumab as maintenance therapy for advanced bladder cancer.
Discover how innovative spacing techniques in cancer treatment enhance radiation effectiveness while minimizing adverse effects for better patient outcomes.
A study analyzes the impact of spacers on biochemical control in prostate cancer patients, revealing significant differences in outcomes.
Dr Colette Shen discusses the promising future of NBTXR3 in cancer treatment, exploring its potential across various tumor types and ongoing trials.
Dr. Colette Shen discusses promising safety and efficacy results of NBTXR3 in treating recurrent head and neck cancer, highlighting unexpected patient responses.
Dr Colette Shen discusses the innovative Study 1100, exploring NBTXR3's safety and efficacy in treating recurrent head and neck cancer.
Binod Dhakal, MD, discusses the extended follow-up of combination selinexor in the proteasome inhibitor–naive subgroup of patients with multiple myeloma.
Researchers uncover that rectal spacers significantly enhance cancer cure rates, reducing treatment failure by 50% in prostate cancer patients.
Discover how rectal spacers revolutionize prostate cancer treatment by reducing side effects and enhancing radiation dose delivery for better patient outcomes.
Amer Zeidan, MBBS, discusses common adverse events and toxicity management for imetelstat in patients with myelodysplastic syndromes.
Discover how NBTXR3 enhances radiation therapy for head and neck cancer, boosting treatment efficacy while protecting healthy tissue.